Caribou Biosciences (CRBU)
Market Price (2/18/2026): $1.54 | Market Cap: $143.7 MilSector: Health Care | Industry: Biotechnology
Caribou Biosciences (CRBU)
Market Price (2/18/2026): $1.54Market Cap: $143.7 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -84% | Weak multi-year price returns2Y Excs Rtn is -115%, 3Y Excs Rtn is -145% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -147 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1577% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -35% | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -19% | |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. | Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 149% | |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1352%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1374% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -113% | ||
| Key risksCRBU key risks include [1] its history of operating losses and the need for significant additional financing to fund development, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -84% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -35% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -115%, 3Y Excs Rtn is -145% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -147 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1577% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -19% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 149% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1352%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1374% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -113% |
| Key risksCRBU key risks include [1] its history of operating losses and the need for significant additional financing to fund development, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Caribou Biosciences (CRBU) stock has lost about 35% since 10/31/2025 because of the following key factors:
1. Caribou Biosciences significantly lowered its projected terminal growth rate from 10% to 1%, indicating a bleak long-term outlook on its ability to generate sustainable revenue growth. This revision reflects reduced confidence in the company's future financial performance and potential for market expansion.
2. The company announced plans to reduce its workforce by approximately 32%. This substantial workforce reduction signals significant operational challenges and potential financial instability, suggesting a need to conserve capital amidst ongoing development costs.
Show more
1. Caribou Biosciences significantly lowered its projected terminal growth rate from 10% to 1%, indicating a bleak long-term outlook on its ability to generate sustainable revenue growth. This revision reflects reduced confidence in the company's future financial performance and potential for market expansion.
2. The company announced plans to reduce its workforce by approximately 32%. This substantial workforce reduction signals significant operational challenges and potential financial instability, suggesting a need to conserve capital amidst ongoing development costs.
Show more
Stock Movement Drivers
Fundamental Drivers
The -36.0% change in CRBU stock from 10/31/2025 to 2/17/2026 was primarily driven by a -37.0% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2172026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.42 | 1.55 | -36.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 9 | 9 | 1.9% |
| P/S Multiple | 24.7 | 15.6 | -37.0% |
| Shares Outstanding (Mil) | 93 | 93 | -0.3% |
| Cumulative Contribution | -36.0% |
Market Drivers
10/31/2025 to 2/17/2026| Return | Correlation | |
|---|---|---|
| CRBU | -36.0% | |
| Market (SPY) | 0.1% | 57.7% |
| Sector (XLV) | 9.1% | 38.5% |
Fundamental Drivers
The -23.6% change in CRBU stock from 7/31/2025 to 2/17/2026 was primarily driven by a -18.0% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 2172026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.03 | 1.55 | -23.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 10 | 9 | -6.3% |
| P/S Multiple | 19.0 | 15.6 | -18.0% |
| Shares Outstanding (Mil) | 93 | 93 | -0.7% |
| Cumulative Contribution | -23.6% |
Market Drivers
7/31/2025 to 2/17/2026| Return | Correlation | |
|---|---|---|
| CRBU | -23.6% | |
| Market (SPY) | 8.3% | 45.3% |
| Sector (XLV) | 21.2% | 33.3% |
Fundamental Drivers
The 8.4% change in CRBU stock from 1/31/2025 to 2/17/2026 was primarily driven by a 38.0% change in the company's P/S Multiple.| (LTM values as of) | 1312025 | 2172026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.43 | 1.55 | 8.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 11 | 9 | -19.0% |
| P/S Multiple | 11.3 | 15.6 | 38.0% |
| Shares Outstanding (Mil) | 90 | 93 | -3.0% |
| Cumulative Contribution | 8.4% |
Market Drivers
1/31/2025 to 2/17/2026| Return | Correlation | |
|---|---|---|
| CRBU | 8.4% | |
| Market (SPY) | 14.5% | 37.4% |
| Sector (XLV) | 8.6% | 34.8% |
Fundamental Drivers
The -78.5% change in CRBU stock from 1/31/2023 to 2/17/2026 was primarily driven by a -54.9% change in the company's P/S Multiple.| (LTM values as of) | 1312023 | 2172026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.21 | 1.55 | -78.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 13 | 9 | -26.9% |
| P/S Multiple | 34.5 | 15.6 | -54.9% |
| Shares Outstanding (Mil) | 61 | 93 | -34.7% |
| Cumulative Contribution | -78.5% |
Market Drivers
1/31/2023 to 2/17/2026| Return | Correlation | |
|---|---|---|
| CRBU | -78.5% | |
| Market (SPY) | 74.2% | 31.4% |
| Sector (XLV) | 23.5% | 26.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CRBU Return | -8% | -58% | -9% | -72% | 0% | -1% | -90% |
| Peers Return | -8% | -58% | -5% | -46% | 10% | 10% | -76% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| CRBU Win Rate | 17% | 33% | 33% | 33% | 42% | 50% | |
| Peers Win Rate | 40% | 33% | 43% | 33% | 53% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| CRBU Max Drawdown | -11% | -66% | -43% | -73% | -54% | -13% | |
| Peers Max Drawdown | -40% | -63% | -37% | -51% | -37% | -9% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: CRSP, ALLO, EDIT, NTLA, BEAM.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/17/2026 (YTD)
How Low Can It Go
| Event | CRBU | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -88.2% | -25.4% |
| % Gain to Breakeven | 746.1% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to CRSP, ALLO, EDIT, NTLA, BEAM
In The Past
Caribou Biosciences's stock fell -88.2% during the 2022 Inflation Shock from a high on 9/7/2021. A -88.2% loss requires a 746.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Caribou Biosciences (CRBU)
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
AI Analysis | Feedback
Here are 1-2 brief analogies for Caribou Biosciences:
- Like an evolution of Kite Pharma or Novartis for cell therapies, but using CRISPR gene editing to create universal 'off-the-shelf' treatments for cancer.
- A CRISPR gene editing company, similar to CRISPR Therapeutics, but with a proprietary platform focused on developing universal 'off-the-shelf' cell therapies for cancer.
AI Analysis | Feedback
- CB-010: An allogeneic anti-CD19 CAR-T cell therapy candidate currently in clinical trials for relapsed or refractory B-cell non-Hodgkin lymphoma.
- CB-011: An allogeneic anti-BCMA CAR-T cell therapy candidate for relapsed or refractory multiple myeloma, currently in preclinical development.
- CB-012: An allogeneic anti-CLL-1 CAR-T cell therapy candidate for relapsed or refractory acute myeloid leukemia, currently in preclinical development.
- ChRDNA Genome-Editing Platform: A proprietary CRISPR hybrid RNA-DNA platform designed to improve the specificity and precision of genome editing for therapeutic applications.
AI Analysis | Feedback
Caribou Biosciences (CRBU) sells primarily to other companies. Its major customer is:- AbbVie Inc. (ABBV)
For the fiscal year ended December 31, 2023, AbbVie Inc. accounted for 100% of Caribou Biosciences' revenue. In prior periods, Novartis Pharma AG (NVS) was also a significant collaboration partner; however, their collaboration agreement was terminated in 2023.
AI Analysis | Feedback
nullAI Analysis | Feedback
Rachel Haurwitz, PhD, President and Chief Executive Officer
Rachel Haurwitz is a co-founder of Caribou Biosciences, established in 2011, and has served as its President and Chief Executive Officer and a director since the company's inception. She is also a co-founder of Intellia Therapeutics. Haurwitz is an inventor on patents and patent applications related to multiple CRISPR-based technologies. Prior to founding Caribou, she conducted research on CRISPR-Cas biology as a graduate student in Jennifer Doudna's laboratory at the University of California, Berkeley, where she earned her Ph.D. in Molecular and Cell Biology.
Sri Ryali, MBA, Chief Financial Officer
Sri Ryali serves as the Chief Financial Officer for Caribou Biosciences, overseeing corporate finance, accounting, investor relations, and corporate communications. He previously held the position of Chief Financial Officer at Codexis, Inc., a publicly traded enzyme engineering company. Before that, he was the Chief Financial Officer of Eiger BioPharmaceuticals, Inc., a publicly traded, commercial-stage company. Ryali also held various roles of increasing responsibility at Aimmune Therapeutics, Inc., including Vice President of Finance. His career demonstrates a pattern of managing publicly traded or commercial-stage biopharmaceutical companies.
Tina Albertson, MD, PhD, Chief Medical Officer
Tina Albertson is the Chief Medical Officer at Caribou Biosciences.
Tim Kelly, Chief Technology Officer
Tim Kelly is the Chief Technology Officer at Caribou Biosciences. He joined Caribou from Oxford Biomedica Solutions, where he was the Chief Executive Officer and board chair. Prior to that, he served as Chief Operating Officer at Homology Medicines, Inc., where he was responsible for operations, process and platform development, and product manufacturing strategy for gene therapy and gene editing technology. His earlier experience includes leading technical operations at Sarepta, Shire, UCB, and Biogen. Kelly also served as a fighter pilot in the U.S. Air Force.
Ruhi Khan, Chief Business Officer
Ruhi Khan serves as the Chief Business Officer for Caribou Biosciences, where she is responsible for developing and executing business development strategy. She brings over 20 years of experience in business development and investment management within the biotechnology and pharmaceutical industries. Most recently, Khan founded an advisory firm that provided business development and finance advice to life sciences companies, and she has extensive senior management experience as the head of business development for several oncology-focused companies.
AI Analysis | Feedback
Here are the key risks to Caribou Biosciences (CRBU):
- Need for Additional Financing and History of Operating Losses: Caribou Biosciences has a history of significant net operating losses and expects these losses to continue for the foreseeable future. The company requires substantial additional financing to fund the development of its product candidates and to implement its operating plans. Failure to secure this funding could significantly delay or prevent the completion of development and commercialization of its product candidates. The company's cash runway is limited, and it anticipates needing future equity raises, especially to fund pivotal clinical trials.
- Clinical Development and Regulatory Uncertainty: The success of Caribou Biosciences' business is highly dependent on the successful completion of clinical trials for its product candidates and obtaining regulatory approvals. There are inherent risks and uncertainties in the development of allogeneic CAR-T cell therapy products, including the possibility that initial or interim clinical trial data may not accurately predict the safety and efficacy of product candidates in larger or later-stage trials. The regulatory approval process for novel CRISPR genome-editing technologies is uncertain, potentially more expensive, and time-consuming, and changes in regulatory requirements could adversely affect the company's ability to bring products to market.
- Limited Market Potential and Intense Competition: The market potential for some of Caribou's product candidates, such as CB-010, may be constrained by specific requirements like HLA matching. Furthermore, the biotechnology sector is highly competitive, and increasing competition could impact Caribou's market position and future revenue generation. The company's valuation is largely driven by the anticipation of future breakthroughs rather than current profitability, increasing its exposure to market volatility if expectations are not met.
AI Analysis | Feedback
The increasing efficacy and adoption of bispecific antibodies in oncology presents an emerging threat. Bispecific antibodies offer a simpler, off-the-shelf therapeutic option that can be more easily administered and potentially less costly than complex allogeneic CAR-T/NK cell therapies. As these antibodies continue to advance clinically and gain market share, they could reduce the addressable patient population and overall market opportunity for Caribou Biosciences' cell therapy candidates, particularly in indications where both modalities compete for similar patient populations.
AI Analysis | Feedback
Caribou Biosciences (CRBU) is developing allogeneic CAR-T cell therapies for various oncology indications. Their main product candidates and their addressable markets are outlined below:CB-010 (Vispa-cel) for Relapsed or Refractory B cell Non-Hodgkin Lymphoma (r/r B-NHL), particularly Second-Line Large B cell Lymphoma (2L LBCL)
The global market for B-cell lymphoma therapeutics was valued at approximately USD 5.08 billion in 2024 and is projected to reach USD 10 billion by 2034. Within this, the diffuse large B-cell lymphoma (DLBCL) therapeutics market, a common subtype of non-Hodgkin lymphoma that CB-010 targets, was valued at USD 3,907.8 million in 2023 and is anticipated to reach USD 5,257.7 million by 2034 globally. The overall CAR T-cell therapy market for lymphoma indications accounted for a significant share of the global CAR T-cell therapy market, representing 50% of the revenue in 2024 and 54.50% in 2024. The CAR-T market specifically for large B-cell lymphoma is projected to grow at a Compound Annual Growth Rate (CAGR) of 14% during the forecast period.CB-011 for Relapsed or Refractory Multiple Myeloma (r/r MM)
The global multiple myeloma market size reached USD 16.4 billion in 2023 and is projected to grow to USD 38.1 billion by 2034 across the seven major markets (7MM), which typically include the U.S., Germany, France, Italy, Spain, the UK, and Japan. The multiple myeloma segment captured the major share of the global CAR T-cell therapy market in 2024 and is expected to continue its dominance. The BCMA-targeted CAR T-cell therapy segment, which CB-011 addresses, is the fastest-growing segment in the CAR T-cell therapy market, with a projected CAGR of 27.3% from 2025 to 2033. Furthermore, the multiple myeloma market within the CAR T-cell therapy landscape is poised for a 14.45% CAGR to 2030 globally.CB-012 for Relapsed or Refractory Acute Myeloid Leukemia (r/r AML)
Caribou Biosciences has halted the AMpLify Phase 1 trial for CB-012 to prioritize its lead oncology programs, CB-010 and CB-011. Therefore, this is no longer a main product in active development.AI Analysis | Feedback
Caribou Biosciences (CRBU) is poised for potential future revenue growth over the next 2-3 years, driven primarily by advancements in its clinical pipeline and the inherent advantages of its CRISPR-edited allogeneic cell therapy platform. While the company currently generates limited licensing and collaboration revenue, future growth is anticipated to stem from key milestones in its lead product candidates. Here are the expected drivers of future revenue growth:- Advancement and Potential Approval of CB-010 (Vispa-cel): Caribou's lead product candidate, CB-010, an allogeneic anti-CD19 CAR-T cell therapy for relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL), is a significant growth driver. The company has reported positive data from its ANTLER Phase 1 clinical trial, demonstrating efficacy and durability comparable to autologous CAR-T therapies. Caribou plans to present further data in the second half of 2025 and is in discussions with the FDA regarding a potential pivotal Phase 3 clinical trial to be initiated following alignment. Successful progression through trials and eventual regulatory approval and commercialization of CB-010 would represent a substantial new revenue stream.
- Clinical Progress and Expansion of CB-011 (CaMMouflage): CB-011, an allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma (r/r MM), has also shown promising first-in-human results from its CaMMouflage Phase 1 clinical trial. Caribou plans to present dose escalation data in the second half of 2025 and intends to move into the dose expansion phase. Continued positive clinical data and advancement of CB-011 through later-stage trials would pave the way for its potential market entry and contribute to future revenue.
- Leveraging its CRISPR Technology Platform and "Off-the-Shelf" Approach: Caribou's next-generation CRISPR technology platform, chRDNA, and its focus on allogeneic (off-the-shelf) cell therapies provide a competitive advantage. This approach aims to offer reduced manufacturing complexity, lower costs, and broader patient accessibility compared to autologous therapies. The successful development and commercialization of these "off-the-shelf" therapies across its pipeline could enable significant market penetration and drive revenue growth in the long term.
- Strategic Collaborations and Partnerships: While current licensing and collaboration revenue has seen a decrease, future strategic initiatives, collaborations, and licensing agreements could significantly influence Caribou's growth trajectory by leveraging external expertise and resources, expanding its pipeline, and broadening its market presence.
AI Analysis | Feedback
Share Issuance
- Caribou Biosciences completed an initial public offering (IPO) in 2021.
- In the third quarter of 2023, Caribou completed an underwritten public offering, issuing 22,115,384 shares of common stock and generating approximately $134.6 million in net proceeds.
- The number of outstanding shares increased by 4.28% in the year leading up to November 5, 2025.
Inbound Investments
- Caribou secured $115 million in an oversubscribed Series C financing round in 2021 to advance its pipeline of allogeneic immune cell therapies and next-generation CRISPR technology platform.
- In March 2021, The Leukemia & Lymphoma Society (LLS) made an equity investment in Caribou Biosciences.
- Pfizer Inc. made a $25 million equity investment in Caribou on June 30, 2023, purchasing 4,690,431 common shares at $5.33 per share, with proceeds used to advance CB-011.
Capital Expenditures
- For the last 12 months as of November 5, 2025, capital expenditures totaled -$2.65 million.
- Projected capital expenditures include $3 million for 2025, $3 million for 2026, and $4 million for 2027.
- These capital expenditures are primarily focused on maintaining and expanding their corporate headquarters and research and development facilities.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Caribou Biosciences Earnings Notes | 12/16/2025 | |
| Would You Still Hold Caribou Biosciences Stock If It Fell Another 30%? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to CRBU.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 01302026 | VEEV | Veeva Systems | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -14.6% | -14.6% | -15.7% |
| 01162026 | BIIB | Biogen | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 19.5% | 19.5% | 0.0% |
| 01162026 | BMRN | BioMarin Pharmaceutical | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 9.7% | 9.7% | 0.0% |
| 01162026 | DOCS | Doximity | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -39.4% | -39.4% | -40.1% |
| 01022026 | CORT | Corcept Therapeutics | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 4.6% | 4.6% | -9.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 7.19 |
| Mkt Cap | 0.9 |
| Rev LTM | 28 |
| Op Inc LTM | -346 |
| FCF LTM | -267 |
| FCF 3Y Avg | -236 |
| CFO LTM | -259 |
| CFO 3Y Avg | -228 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -54.5% |
| Rev Chg 3Y Avg | 34.7% |
| Rev Chg Q | 8.6% |
| QoQ Delta Rev Chg LTM | 1.9% |
| Op Mgn LTM | -834.6% |
| Op Mgn 3Y Avg | -749.0% |
| QoQ Delta Op Mgn LTM | 131.8% |
| CFO/Rev LTM | -660.5% |
| CFO/Rev 3Y Avg | -599.5% |
| FCF/Rev LTM | -674.9% |
| FCF/Rev 3Y Avg | -613.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.9 |
| P/S | 19.5 |
| P/EBIT | -2.5 |
| P/E | -2.6 |
| P/CFO | -3.2 |
| Total Yield | -38.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -39.2% |
| D/E | 0.1 |
| Net D/E | -0.4 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -1.4% |
| 3M Rtn | 12.4% |
| 6M Rtn | 8.5% |
| 12M Rtn | 10.6% |
| 3Y Rtn | -69.9% |
| 1M Excs Rtn | 0.2% |
| 3M Excs Rtn | 13.9% |
| 6M Excs Rtn | -6.0% |
| 12M Excs Rtn | 12.6% |
| 3Y Excs Rtn | -137.2% |
Price Behavior
Price Behavior
| Market Price | $1.55 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 07/23/2021 | |
| Distance from 52W High | -45.4% | |
| 50 Days | 200 Days | |
| DMA Price | $1.63 | $1.74 |
| DMA Trend | up | down |
| Distance from DMA | -5.0% | -10.7% |
| 3M | 1YR | |
| Volatility | 64.0% | 89.9% |
| Downside Capture | 434.64 | 260.59 |
| Upside Capture | 249.77 | 244.68 |
| Correlation (SPY) | 53.3% | 37.4% |
CRBU Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.36 | 3.24 | 3.49 | 3.22 | 1.69 | 1.82 |
| Up Beta | 10.86 | 7.27 | 2.90 | 1.41 | 1.17 | 1.62 |
| Down Beta | 0.76 | 0.88 | 2.72 | 3.14 | 1.52 | 1.80 |
| Up Capture | 176% | 237% | 231% | 394% | 471% | 308% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 8 | 15 | 23 | 55 | 118 | 326 |
| Down Capture | 522% | 470% | 409% | 311% | 155% | 113% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 10 | 23 | 33 | 65 | 124 | 397 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CRBU | |
|---|---|---|---|---|
| CRBU | 16.7% | 89.9% | 0.57 | - |
| Sector ETF (XLV) | 9.0% | 17.4% | 0.34 | 34.8% |
| Equity (SPY) | 13.0% | 19.4% | 0.51 | 37.4% |
| Gold (GLD) | 67.2% | 25.5% | 1.99 | 7.8% |
| Commodities (DBC) | 5.2% | 16.8% | 0.13 | 8.2% |
| Real Estate (VNQ) | 7.8% | 16.6% | 0.28 | 22.8% |
| Bitcoin (BTCUSD) | -28.8% | 44.9% | -0.62 | 26.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CRBU | |
|---|---|---|---|---|
| CRBU | -37.8% | 87.7% | -0.20 | - |
| Sector ETF (XLV) | 7.9% | 14.5% | 0.36 | 29.1% |
| Equity (SPY) | 13.3% | 17.0% | 0.62 | 36.5% |
| Gold (GLD) | 21.3% | 17.1% | 1.02 | 7.6% |
| Commodities (DBC) | 10.2% | 18.9% | 0.42 | 4.9% |
| Real Estate (VNQ) | 5.3% | 18.8% | 0.19 | 30.4% |
| Bitcoin (BTCUSD) | 8.2% | 57.2% | 0.36 | 23.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CRBU | |
|---|---|---|---|---|
| CRBU | -21.1% | 87.7% | -0.20 | - |
| Sector ETF (XLV) | 11.3% | 16.5% | 0.57 | 29.1% |
| Equity (SPY) | 15.8% | 17.9% | 0.76 | 36.5% |
| Gold (GLD) | 14.8% | 15.6% | 0.79 | 7.6% |
| Commodities (DBC) | 8.0% | 17.6% | 0.37 | 4.9% |
| Real Estate (VNQ) | 6.8% | 20.7% | 0.29 | 30.4% |
| Bitcoin (BTCUSD) | 68.5% | 66.7% | 1.08 | 23.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/3/2025 | 0.4% | -13.6% | -23.1% |
| 8/12/2025 | 8.9% | -1.1% | 6.7% |
| 3/10/2025 | -3.2% | -7.7% | -28.5% |
| 11/6/2024 | 1.1% | -20.0% | -22.5% |
| 7/16/2024 | -3.3% | -12.1% | -30.4% |
| 3/11/2024 | -30.5% | -27.6% | -39.8% |
| 11/7/2023 | -5.0% | -11.5% | 24.7% |
| 7/13/2023 | -22.6% | -18.7% | -14.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 4 | 3 |
| # Negative | 6 | 9 | 10 |
| Median Positive | 5.2% | 5.3% | 24.7% |
| Median Negative | -5.5% | -12.1% | -22.3% |
| Max Positive | 14.3% | 32.1% | 46.1% |
| Max Negative | -30.5% | -27.6% | -39.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/10/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/11/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/09/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
| 12/31/2021 | 03/21/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Haurwitz, Rachel E | President and CEO | Trust | Buy | 3172025 | 1.02 | 20,000 | 20,400 | 3,436,783 | Form |
| 2 | McClung, Barbara G | Chief Legal Officer | Direct | Sell | 2212025 | 1.35 | 3,564 | 4,811 | 598,728 | Form |
| 3 | Khan, Ruhi Ahmad | Chief Business Officer | Direct | Sell | 2212025 | 1.35 | 3,564 | 4,811 | 90,364 | Form |
| 4 | Kanner, Steven | Chief Scientific Officer | Direct | Sell | 2212025 | 1.35 | 3,564 | 4,811 | 582,601 | Form |
| 5 | Ryali, Sriram | Chief Financial Officer | Direct | Buy | 1302025 | 1.42 | 17,360 | 24,651 | 24,651 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.